CA2573745A1 - Immunoglobulins comprising predominantly a glcnac2man3glcnac2 glycoform - Google Patents

Immunoglobulins comprising predominantly a glcnac2man3glcnac2 glycoform Download PDF

Info

Publication number
CA2573745A1
CA2573745A1 CA002573745A CA2573745A CA2573745A1 CA 2573745 A1 CA2573745 A1 CA 2573745A1 CA 002573745 A CA002573745 A CA 002573745A CA 2573745 A CA2573745 A CA 2573745A CA 2573745 A1 CA2573745 A1 CA 2573745A1
Authority
CA
Canada
Prior art keywords
composition
immunoglobulins
glycan
antibody
immunoglobulin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002573745A
Other languages
English (en)
French (fr)
Inventor
Tillman U. Gerngross
Huijuan Li
Stefan Wildt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glycofi Inc
Original Assignee
Glycofi, Inc.
Tillman U. Gerngross
Huijuan Li
Stefan Wildt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glycofi, Inc., Tillman U. Gerngross, Huijuan Li, Stefan Wildt filed Critical Glycofi, Inc.
Publication of CA2573745A1 publication Critical patent/CA2573745A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA002573745A 2004-07-21 2005-07-19 Immunoglobulins comprising predominantly a glcnac2man3glcnac2 glycoform Abandoned CA2573745A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US59005104P 2004-07-21 2004-07-21
US59001104P 2004-07-21 2004-07-21
US60/590,011 2004-07-21
US60/590,051 2004-07-21
PCT/US2005/025652 WO2006014679A1 (en) 2004-07-21 2005-07-19 Immunoglobulins comprising predominantly a glcnac2man3glcnac2 glycoform

Publications (1)

Publication Number Publication Date
CA2573745A1 true CA2573745A1 (en) 2007-01-12

Family

ID=35262113

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002573745A Abandoned CA2573745A1 (en) 2004-07-21 2005-07-19 Immunoglobulins comprising predominantly a glcnac2man3glcnac2 glycoform

Country Status (5)

Country Link
EP (1) EP1776385A1 (de)
JP (1) JP2008512353A (de)
AU (1) AU2005269759A1 (de)
CA (1) CA2573745A1 (de)
WO (1) WO2006014679A1 (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7449308B2 (en) 2000-06-28 2008-11-11 Glycofi, Inc. Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
US7332299B2 (en) 2003-02-20 2008-02-19 Glycofi, Inc. Endomannosidases in the modification of glycoproteins in eukaryotes
CA2599688A1 (en) * 2005-03-01 2006-09-08 Wyeth Cinnoline compounds and their use as liver x receptor modulators
AU2007205935B2 (en) 2006-01-17 2013-07-11 Synthon Biopharmaceuticals B.V. Compositions and methods for humanization and optimization of N-glycans in plants
US7923011B2 (en) 2006-10-12 2011-04-12 Genentech, Inc. Antibodies to lymphotoxin-alpha
JP2010534710A (ja) * 2007-08-01 2010-11-11 グラクソ グループ リミテッド 新規抗体
EP2340305A1 (de) 2008-09-26 2011-07-06 Eureka Therapeutics, Inc. Zelllinien und proteine mit unterschiedlichen glykosylierungsmustern
TW201028431A (en) * 2008-10-31 2010-08-01 Lonza Ag Novel tools for the production of glycosylated proteins in host cells
AR074777A1 (es) 2008-12-19 2011-02-09 Glaxo Group Ltd Proteinas de union a antigeno
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
EP2459590B1 (de) * 2009-07-30 2015-04-22 F.Hoffmann-La Roche Ag Enzymatische antikörperverarbeitung
PE20121702A1 (es) 2010-01-28 2012-12-14 Glaxo Group Ltd Proteinas de enlace cd127
EA201290630A1 (ru) 2010-02-09 2013-03-29 Глаксо Груп Лимитед Лечение расстройства обмена веществ
UA108227C2 (xx) 2010-03-03 2015-04-10 Антигензв'язуючий білок
UY33421A (es) 2010-06-03 2011-12-30 Glaxo Wellcome House Proteinas de union al antígeno humanizados
BR112013012627A2 (pt) 2010-11-23 2016-10-04 Glaxo Group Ltd proteína de ligação de antígeno, polinucleotídeo, composição farmacêutica, e uso da referida composição
MX2013005847A (es) 2010-11-24 2013-12-12 Glaxo Group Ltd Proteinas de union a antigeno multiespecificas que eligen como blanco a hgf.
CN106279418A (zh) 2011-05-27 2017-01-04 葛兰素集团有限公司 Bcma（cd269/tnfrsf17）结合蛋白
EP2736925A2 (de) 2011-07-27 2014-06-04 Glaxo Group Limited Mit fc-domänen fusionierbare anti-vegf-einzelvariablen-domänen
WO2014029752A1 (en) 2012-08-22 2014-02-27 Glaxo Group Limited Anti lrp6 antibodies
EP3712177A1 (de) 2013-03-15 2020-09-23 GlaxoSmithKline Intellectual Property Development Limited Anti-lag-3 bindende proteine
CR20170060A (es) 2014-08-19 2017-04-18 Merck Sharp & Dohme Anticuerpos anti tigit
WO2016059602A2 (en) 2014-10-16 2016-04-21 Glaxo Group Limited Methods of treating cancer and related compositions
CN108699145A (zh) 2015-09-02 2018-10-23 伊缪泰普有限公司 抗lag-3抗体
JO3555B1 (ar) 2015-10-29 2020-07-05 Merck Sharp & Dohme جسم مضاد يبطل فعالية فيروس الالتهاب الرئوي البشري
AU2017247796A1 (en) 2016-04-05 2018-09-27 Glaxosmithkline Intellectual Property Development Limited Inhibition of TGFBeta in immunotherapy
NL2017270B1 (en) 2016-08-02 2018-02-09 Aduro Biotech Holdings Europe B V New anti-hCTLA-4 antibodies
JOP20190055A1 (ar) 2016-09-26 2019-03-24 Merck Sharp & Dohme أجسام مضادة ضد cd27
WO2018102746A1 (en) 2016-12-02 2018-06-07 Rigel Pharmaceuticals, Inc. Antigen binding molecules to tigit
US11230601B2 (en) 2017-10-10 2022-01-25 Tilos Therapeutics, Inc. Methods of using anti-lap antibodies
CN113164780A (zh) 2018-10-10 2021-07-23 泰洛斯治疗公司 抗lap抗体变体及其用途
WO2021207449A1 (en) 2020-04-09 2021-10-14 Merck Sharp & Dohme Corp. Affinity matured anti-lap antibodies and uses thereof
JP2023551935A (ja) 2020-12-02 2023-12-13 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド Ｉｌ－７結合タンパク質および医学的療法におけるそれらの使用
JP2024521187A (ja) 2021-05-28 2024-05-28 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド ガンの治療のための組み合わせ療法
AU2022327859A1 (en) 2021-08-13 2024-02-22 Glaxosmithkline Intellectual Property Development Limited Cytotoxicity targeting chimeras
WO2023017483A1 (en) 2021-08-13 2023-02-16 Glaxosmithkline Intellectual Property Development Limited Cytotoxicity targeting chimeras for ccr2-expressing cells
CA3233953A1 (en) 2021-10-05 2023-04-13 Matthew Bruce Combination therapies for treating cancer
WO2023161874A1 (en) 2022-02-25 2023-08-31 Glaxosmithkline Intellectual Property Development Limited Cytotoxicity targeting chimeras for c-c chemokine receptor 2-expressing cells
WO2023161878A1 (en) 2022-02-25 2023-08-31 Glaxosmithkline Intellectual Property Development Limited Cytotoxicity targeting chimeras for folate receptor-expressing cells
WO2023161879A1 (en) 2022-02-25 2023-08-31 Glaxosmithkline Intellectual Property Development Limited Cytotoxicity targeting chimeras for fibroblast activation protein-expressing cells
WO2023161877A1 (en) 2022-02-25 2023-08-31 Glaxosmithkline Intellectual Property Development Limited Cytotoxicity targeting chimeras for integrin avb6-expressing cells
WO2023161875A1 (en) 2022-02-25 2023-08-31 Glaxosmithkline Intellectual Property Development Limited Cytotoxicity targeting chimeras for prostate specific membrane antigen-expressing cells
WO2023161876A1 (en) 2022-02-25 2023-08-31 Glaxosmithkline Intellectual Property Development Limited Cytotoxicity targeting chimeras for cxcr3-expressing cells
WO2023161881A1 (en) 2022-02-25 2023-08-31 Glaxosmithkline Intellectual Property Development Limited Cytotoxicity targeting chimeras for ccr2-expressing cells
US20230348604A1 (en) 2022-04-29 2023-11-02 23Andme, Inc. Antigen binding proteins
WO2023227641A1 (en) 2022-05-27 2023-11-30 Glaxosmithkline Intellectual Property Development Limited Use of tnf-alpha binding proteins and il-7 binding proteins in medical treatment
WO2024042112A1 (en) 2022-08-25 2024-02-29 Glaxosmithkline Intellectual Property Development Limited Antigen binding proteins and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE419009T1 (de) * 1997-10-31 2009-01-15 Genentech Inc Methoden und zusammensetzungen bestehend aus glykoprotein-glykoformen
US7449308B2 (en) * 2000-06-28 2008-11-11 Glycofi, Inc. Combinatorial DNA library for producing modified N-glycans in lower eukaryotes

Also Published As

Publication number Publication date
JP2008512353A (ja) 2008-04-24
AU2005269759A1 (en) 2006-02-09
EP1776385A1 (de) 2007-04-25
WO2006014679A1 (en) 2006-02-09

Similar Documents

Publication Publication Date Title
US20060029604A1 (en) Immunoglobulins comprising predominantly a GlcNAc2Man3GlcNAc2 glycoform
US20060024292A1 (en) Immunoglobulins comprising predominantly a Gal2GlcNAc2Man3GlcNAc2 glycoform
CA2573745A1 (en) Immunoglobulins comprising predominantly a glcnac2man3glcnac2 glycoform
US20060034829A1 (en) Immunoglobulins comprising predominantly a MAN3GLCNAC2 glycoform
US20060034830A1 (en) Immunoglobulins comprising predominantly a GalGlcNAcMan5GLcNAc2 glycoform
US20060034828A1 (en) Immunoglobulins comprising predominantly a GlcNAcMAN5GLCNAC2 glycoform
US20060024304A1 (en) Immunoglobulins comprising predominantly a Man5GlcNAc2 glycoform
US20060257399A1 (en) Immunoglobulins comprising predominantly a Man5GIcNAc2 glycoform
AU2005269763A1 (en) Immunoglobulins comprising predominantly a Gal2GlcNac2Man3GlcNac2 glycoform
WO2006071856A2 (en) Immunoglobulins comprising predominantly a man5glcnac2 glycoform
CA2573541A1 (en) Immunoglobulins comprising predominantly a man3glcnac2 glycoform
US20090226464A1 (en) Immunoglobulins comprising predominantly a glcnacman3glcnac2 glycoform
CA2620515A1 (en) Immunoglobulins comprising predominantly a glcnacman3glcnac2 glycoform
CA2590441A1 (en) Immunoglobulins comprising predominantly a ga1glcnacman5glcnac2 glycoform
CA2573554A1 (en) Immunoglobulins comprising predominantly a man5glcnac2 glycoform
CA2573864A1 (en) Immunoglobulins comprising predominantly a glcnacman5glcnac2 glycoform
CN101001875A (zh) 主要包含man5glcnac2糖形的免疫球蛋白
CN101001876A (zh) 包含占优势的GlcNacMAN5GLCNAC2糖形的免疫球蛋白

Legal Events

Date Code Title Description
FZDE Dead